Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 12
HOS-086197 · Präparat HOS-083284
Methadone1 5, single dose 500 q12h, ↓ 36% ↓ 38%
Increased methadone dose may be necessary when concomitantly administered with
ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer due to
induction of glucuronidation. Dose adjustment should be considered based on the
patient’s clinical response to methadone therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 97cf86d486910b4535f00595061c0c0c7dcb34db71587267e0dbffb34e978187 · Zeichen 11792–12347 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 45
HOS-086409 · Präparat HOS-083284
Methadone1 5, single dose 500 q12h, ↓ 36% ↓ 38%
Increased methadone dose may be necessary when concomitantly administered with
ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer due to
induction of glucuronidation. Dose adjustment should be considered based on the
patient’s clinical response to methadone therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d9a70c5555657b4e8b462e0d3d2cef3aebc5b52b4ac1ba43a5bdcbbf93fb3ce5 · Zeichen 12784–13347 im Abschnitt
Wechselwirkungen · Exelon
Exelon 1.5 mg hard capsules Exelon 3.0 mg hard capsules Exelon 4.5 mg hard capsules Exelon 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-087795 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1110–1692 im Abschnitt
Wechselwirkungen · Exelon
Exelon 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 22
HOS-087828 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1111–1693 im Abschnitt
Wechselwirkungen · Exelon
Exelon 4.6 mg/24 h transdermal patch Exelon 9.5 mg/24 h transdermal patch Exelon 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 39
HOS-087855 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage ff4a6089869c9cad9b1692c6af2335103d7143b0e75d26f251dc054a8dc03d56 · Zeichen 1197–1695 im Abschnitt
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088137 · Präparat HOS-083615
ANALGESICS/OPIOIDS
Methadone Individual Methadone AUC 0.40 Methadone-maintained patients
Patient Dosing (0.31-0.51) beginning Viramune therapy
Methadone Cmin ND should be monitored for evidence
Methadone Cmax 0.58 (0.50-0.67) of withdrawal and methadone dose
should be adjusted accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 3aea152e9711d02f1240c9e5939e7b124f3712afb41da8a16d48b83b4bf350b5 · Zeichen 23523–24001 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 39–40
HOS-088228 · Präparat HOS-083615
39
ANALGESICS/OPIOIDS
Methadone Individual Methadone AUC 0.40 Methadone-maintained patients
Patient Dosing (0.31-0.51) beginning Viramune therapy
Methadone Cmin ND should be monitored for evidence
Methadone Cmax 0.58 (0.50-0.67) of withdrawal and methadone dose
should be adjusted accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage c3d1ec15d945404f6f6853bacd3f57ba64f92a8031cfd729afc050ad8c7f3294 · Zeichen 23710–24218 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 65
HOS-088318 · Präparat HOS-083615
ANALGESICS/OPIOIDS
Methadone Individual Methadone AUC 0.40 Methadone-maintained patients
Patient Dosing (0.31-0.51) beginning Viramune therapy
Methadone Cmin ND should be monitored for evidence
Methadone Cmax 0.58 (0.50-0.67) of withdrawal and methadone dose
should be adjusted accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage b1e503b3aa9e5129da787befb1ec5b43602b1e0e38f38ab62df9e66818951204 · Zeichen 23707–24180 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-088517 · Präparat HOS-083663
8
efficacy in case of combination
in the clinical setting. Some
clinical findings also support a
possible interaction between
lamivudine and cladribine
OPIOIDS
Methadone/Lamivudine Interaction not studied. As only limited data are
Methadone/Zidovudine Zidovudine AUC 43% available the clinical
(30 to 90 mg once daily/200 mg Methadone AUC significance is not known.
every 4 hours) Monitor for signs of
zidovudine toxicity (see
section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 14f192002bffc08afb0440dc52306b38bb35a6e271b9e54a60d13d4dfc570fac · Zeichen 7517–8430 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088518 · Präparat HOS-083663
Methadone dosage adjustment
unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
URICOSURIC
Probenecid/Lamivudine Interaction not studied. As only limited data are
Probenecid/Zidovudine Zidovudine AUC 106% available the clinical
(500 mg four times significance is not known.
daily/2mg/kg thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Sorbitol solution (3.2g , 10.2 g, Single dose lamivudine oral When possible, avoid chronic
13.4 g)/ Lamivudine solution 300 mg coadministration of Combivir
with medicinal products
Lamivudine:
containing sorbitol or other
AUC 14%; 32%; 36% osmotic acting poly-alcohols
or monosaccharide alcohols
Cmax 28%; 52%, 55%. (e.g. xylitol, mannitol, lactitol,
maltitol). Consider more
frequent monitoring of HIV-1
viral load when chronic
coadministration cannot be
avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) methadone (HOS-086198) xylitol (HOS-085846) mannitol (HOS-085847) probenecid (HOS-085208) lactitol (HOS-085848) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage c60e9a85277b6d563917784e4dc019a6b2a7eb8117d4abdfd711dea58f60eabc · Zeichen 8504–10729 im Abschnitt
Wechselwirkungen · Ziagen
Ziagen 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-089989 · Präparat HOS-083963
Methadone: in a pharmacokinetic study, co-administration of 600 mg abacavir twice daily with
methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax but the AUC was
unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this
study abacavir increased the mean methadone systemic clearance by 22%. The induction of drug
metabolising enzymes cannot therefore be excluded. Patients being treated with methadone and
abacavir should be monitored for evidence of withdrawal symptoms indicating under dosing, as
occasionally methadone re-titration may be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:13:00Z · SHA-256 5ae0e9d13123c9bc32a3fb0e0e28b30666a7ec0ca822b9a0f255860ec60bcfbd · Passage f41cffb9e6a7d0c480a0a1ddf692ee057383123f08f64d430ac560e19f29daf6 · Zeichen 1229–1848 im Abschnitt
Wechselwirkungen · Ziagen
Ziagen 20 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 25
HOS-090027 · Präparat HOS-083963
Methadone: in a pharmacokinetic study, co-administration of 600 mg abacavir twice daily with
methadone showed a 35% reduction in abacavir Cmax and a one hour delay in tmax but the AUC was
unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this
study abacavir increased the mean methadone systemic clearance by 22%. The induction of drug
metabolising enzymes cannot therefore be excluded. Patients being treated with methadone and
abacavir should be monitored for evidence of withdrawal symptoms indicating under dosing, as
occasionally methadone re-titration may be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:13:00Z · SHA-256 5ae0e9d13123c9bc32a3fb0e0e28b30666a7ec0ca822b9a0f255860ec60bcfbd · Passage f41cffb9e6a7d0c480a0a1ddf692ee057383123f08f64d430ac560e19f29daf6 · Zeichen 1284–1903 im Abschnitt
Wechselwirkungen · Prometax
Prometax 1.5 mg hard capsules Prometax 3.0 mg hard capsules Prometax 4.5 mg hard capsules Prometax 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-090120 · Präparat HOS-084005
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1110–1692 im Abschnitt
Wechselwirkungen · Prometax
Prometax 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 20
HOS-090145 · Präparat HOS-084005
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1111–1693 im Abschnitt
Wechselwirkungen · Prometax
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 35–36
HOS-090171 · Präparat HOS-084005
35
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) diphemanil (HOS-085613) erythromycin (HOS-084514) pentamidine (HOS-085605)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 080f18de9b10d892297d1bc206f9581edfb3428553767b74a8c1d058badc36e8 · Zeichen 1656–1838 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-108569 · Präparat HOS-093047
10
Drugs by Therapeutic Interaction Recommendation
Area Geometric mean change concerning co-
(%) administration
(Possible mechanism)
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant
use of lamivudine with
In vitro lamivudine inhibits the cladribine is not
intracellular phosphorylation of recommended (see section
cladribine leading to a potential 4.4).
risk of cladribine loss of efficacy
in case of combination in the
clinical setting. Some clinical
findings also support a possible
interaction between lamivudine
and cladribine.
OPIOIDS
Methadone/Abacavir Abacavir: AUC As only limited data are
(40 to 90 mg once daily for 14 Cmax 35% available the clinical
days/600 mg single dose, then significance is not known.
600 mg twice daily for 14 Methadone: CL/F 22% Monitor for signs of
days) zidovudine toxicity (see
Methadone/Lamivudine Interaction not studied. section 4.8).
Methadone/Zidovudine Zidovudine AUC 43%
(30 to 90 mg once Methadone AUC Methadone dosage adjustment
daily/200 mg every 4 hours) unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
RETINOIDS
Retinoid compounds Interaction not studied. Insufficient data to
(e.g. isotretinoin)/Abacavir recommend dosage
Possible interaction given adjustment.
common pathway of elimination
via alcohol dehydrogenase.
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Lamivudine
No drug interaction studies
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Zidovudine
URICOSURIC
Probenecid/Abacavir Interaction not studied. As only limited data are
Probenecid/Lamivudine Interaction not studied. available the clinical
Probenecid/Zidovudine Zidovudine AUC 106% significance is not known.
(500 mg four times Monitor for signs of
daily/2 mg/kg thrice daily) (UGT inhibition) zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Ethanol/Abacavir Abacavir: AUC 41% No dosage adjustment
(0.7 g/kg single dose/600 mg Ethanol: AUC necessary.
single dose)
(Inhibition of alcohol
dehydrogenase)
Ethanol/Lamivudine Interaction not studied.
Ethanol/Zidovudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) isotretinoin (HOS-108570) probenecid (HOS-085208) ethanol (HOS-089988) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 779b308db2f1cd8ed7b6c3456196c746580180c3977235a9bdd446b4f2a52234 · Zeichen 9177–13020 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-109023 · Präparat HOS-093083
60
No clinical relevant interaction fluvastatin or pravastatin is
expected. recommended.
Pravastatin is not metabolised by
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations of
methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended dosage,
metabolism. despite the observed induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) methadone (HOS-086198) fluvastatin (HOS-086305) buprenorphine (HOS-086193) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 66795734d42d6453cc3ecae53ffe464f62e190070894ffc9d2f185474a98d737 · Zeichen 57035–59066 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 95–96
HOS-109101 · Präparat HOS-093083
95
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels of
due to CYP3A inhibition by these products have been stabilised.
lopinavir/ritonavir.
Lipid lowering agents
Lovastatin and Lovastatin, Simvastatin: Since increased concentrations of
Simvastatin Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination of
these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
of lomitapide are expected to
increase.
Atorvastatin Atorvastatin: The combination of Kaletra with
AUC: ↑ 5.9-fold atorvastatin is not recommended. If
Cmax: ↑ 4.7-fold the use of atorvastatin is considered
Due to CYP3A inhibition by strictly necessary, the lowest
lopinavir/ritonavir. possible dose of atorvastatin should
be administered with careful safety
monitoring (see section 4.4).
Rosuvastatin, 20 mg QD Rosuvastatin: Caution should be exercised and
AUC: ↑ 2-fold reduced doses should be considered
Cmax: ↑ 5-fold when Kaletra is co-administered
While rosuvastatin is poorly with rosuvastatin (see section 4.4).
metabolised by CYP3A4, an
increase of its plasma
concentrations was observed. The
mechanism of this interaction may
result from inhibition of transport
proteins.
Fluvastatin or Fluvastatin, Pravastatin: If treatment with an HMG-CoA
Pravastatin No clinical relevant interaction reductase inhibitor is indicated,
expected. fluvastatin or pravastatin is
Pravastatin is not metabolised by recommended.
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): methadone (HOS-086198) lovastatin (HOS-086157) atorvastatin (HOS-086304) lomitapide (HOS-086160) simvastatin (HOS-086158) rosuvastatin (HOS-086307) fluvastatin (HOS-086305) buprenorphine (HOS-086193) tacrolimus (HOS-085202) sirolimus (HOS-085172) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8615aceaaf9aeead58e7d8428a116c5869ad8f9e57e471dff2f6359133eeb12b · Zeichen 55116–58920 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-109484 · Präparat HOS-093201
16
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ddbb18c489ccc11c6814ac36e2fb24fd816c63d5b15490877a83dbf46e7d7f5 · Zeichen 27474–31780 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.